Formation of bacteriophage MS2 infectious units in a cell-free translation system

FEBS Letters
V L KatanaevM Siemann

Abstract

We show that a simple cell-free translation system from Escherichia coli, programmed with phage MS2 RNA, is able to infect F+ E. coli cells. The plaques appearing on the E. coli host strain are morphologically indistinguishable from those derived from normal phage MS2 infection. This effect is strictly translation-dependent, since an incomplete translation system or the system inhibited by antibiotics leads to no infection. The cell-free based infection is maximal under conditions favouring the highest synthesis of maturation protein (one of the four phage-encoded proteins). The infection is abolished when RNase A or trypsin treatment is included before addition of cells. Similarly, due to RNA and maturation protein degradation, the continued incubation of the translation mixture under protein synthesis conditions significantly decreases infectivity. These findings suggest the formation of 'minimal infectious units', simple complexes of MS2 RNA and maturation protein. Here we describe the first example of bacteriophage infectious unit formation directly performed in a cell-free translation system. A possible application of this phenomenon might be the construction of newly designed RNA vector delivery systems and, moreover, cou...Continue Reading

References

Jan 1, 1979·Annual Review of Biochemistry·T Blumenthal, G G Carmichael
Mar 13, 1975·Nature·T Shiba, T Miyake
Dec 13, 1991·Science·A MollaE Wimmer
Jan 1, 1991·Progress in Nucleic Acid Research and Molecular Biology·G W WitherellO C Uhlenbeck
Aug 1, 1987·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·R Cedergren, H Grosjean
Dec 20, 1988·Journal of Molecular Biology·D Beckett, O C Uhlenbeck
Mar 24, 1987·Biochemistry·P J RomaniukO C Uhlenbeck
Sep 1, 1974·Acta Endocrinologica·E C Griffiths, K C Hooper
Oct 3, 1973·Nature: New Biology·M Happe, H Jockusch
Mar 23, 1974·FEBS Letters·C Weissmann
Dec 29, 1967·Biochemical and Biophysical Research Communications·E Richelson, D Nathans
Jan 21, 1972·European Journal of Biochemistry·M Kondo, C Weissmann
Aug 23, 1967·Biochemical and Biophysical Research Communications·K EggenD Nathans
Jan 1, 1983·Methods in Enzymology·H Z Chen, G Zubay
Jul 27, 1981·Biochimica Et Biophysica Acta·T Shiba, Y Suzuki
Mar 26, 1982·Science·J HollandS VandePol
Jan 1, 1995·Progress in Nucleic Acid Research and Molecular Biology·A B Chetverin, A S Spirin
Apr 1, 1993·The Journal of General Virology·R A MasticoP G Stockley
Mar 20, 1995·Analytical Biochemistry·L A RyabovaA S Spirin
Oct 1, 1994·The International Journal of Biochemistry·P G StockleyK Valegård
Dec 5, 1993·Journal of Molecular Biology·R GolmohammadiL Liljas
Jan 1, 1993·Methods in Enzymology·V I Baranov, A S Spirin
Dec 1, 1964·Journal of Molecular Biology·J H STRAUSS
Apr 23, 1965·Science·R C VALENTINE, M STRAND

❮ Previous
Next ❯

Citations

Apr 13, 2005·Journal of Biotechnology·Daniel Legendre, Jacques Fastrez
Nov 20, 1998·Current Opinion in Biotechnology·L JermutusA Plückthun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.